Announcements Trials
Browse Landscape

Status

Completed 2Unknown 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 6Neoplasm Metastasis 2Colorectal Neoplasms 2Solid Tumor 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Recurrence 1Pancreatic Cancer Non-resectable 1Pancreatic Adenocarcinoma 1Osteosarcoma 1Neuroblastoma 1Gastrointestinal Neoplasms 1Borderline Resectable Pancreatic Cancer 1Biliary Tract Neoplasms 1Advanced Esophageal Squamous Cell Cancer 1

Interventions

Gemcitabine 9Oxaliplatin 6Cisplatin 6Capecitabine 6durvalumab 4apatinib 4S 1 (combination) 4Irinotecan 4Immune Checkpoint Inhibitors 4surufatinib 3Injections 3Drug Therapy 3pembrolizumab 2lenvatinib 2camrelizumab 2Taxes 2Leucovorin 2Fluorouracil 2Docetaxel 2130-nm albumin-bound paclitaxel 2tremelimumab 1toripalimab 1taxane 1spartalizumab 1sintilimab 1regorafenib 1manganese chloride 1irinotecan sucrosofate 1gimeracil 1gemcitabine-oxaliplatin regimen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Biliary Tract Neoplasms × irinotecan sucrosofate × Clear all
NCT06282120 2024-02-28

Efficacy and Safety of Irinotecan Liposome Injection Combined With 5-FU/LV± Immunotherapy in First-line Gemsitabine + Immunoprogressive Patients With Metastatic Biliary Tract Cancer

Tianjin Medical University Cancer Institute and Hospital

Unknown
30 enrolled
Gastrointestinal

Biliary Tract Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡